ABSTRACT
INTRODUCTION
E strogen receptor (ER) status of breast tumor (expressed as + or -status) is a well-accepted predictor of response to endocrine therapy. In addition, a down-stream marker of functional ER signaling (1), progesterone receptor (PR), is measured in breast cancer (BC) biopsies and surgical samples. Now, it is known that two receptors for estrogen exist: ER and ER , encoded by two different genes: ER is encoded by gene located on chromosomal loci 6q25.1 (2) , and the ER splice variants of both ER and ER , suggests that complex regulation of estrogen action exists. The exact biological significance of isoforms and its splice variants of both receptors (ER and ER ), is still unclear, but it seems that their existence may have regulatory role in the response to estrogen. Both genes, ER and ER , have complex "system" of multiple promoters and differential splicing in 5'-UTR region (4) . Exon deletions or duplications are second mechanism that potentially generates changes in reading frame, and, accordingly, exchanged proteins (5, 6) . In addition, five ER isoforms (designated as ER 1 -ER 5) originate by alternative usage of five 8 th codons (7, 8) . It has been shown that the expression of ER increases during the process of cancerogenesis, but the expression of ER seems to decreases. Estrogen receptor is under intensive investigation and its role in BC appears to be of predictive value, too. It is reasonable to propose that ER status should now include both receptors, ER and ER .
In this study, we measure expression levels of mRNA of two ER variants ER 1 and ER 1 and ER systematic sample of invasive BC. In addition, we compared ER status with ER and PR status. For this purpose, we quantified the expression levels of mRNA of two isoforms of ER gene in 60 samples of primary operable BC samples and in adjacent normal tissue by the real-time RT-PCR. This study was performed by using the sensitive and sequence specific assays based on TaqMan methodology. Relative levels of ER 1 and ER were measured by assays designed to detect these transcript at unique regions.
MATERIAL AND METHODS

Patients
We analyzed 60 samples obtained after surgery from patients with primary breast tumors, hospitalized at the Institute of Oncology and Radiology of Serbia in Belgrade. The study had received Institutional Review Board approval according to the National Health Regulation. Adjacent normal tissues are obtained after total mastectomy. Tissue was stored at liquid nitrogen until RNA and protein isolation. The patients all met the following criteria: primary operable unilateral invasive BC, without previous treatment.
Steroid receptor assay
Steroid receptors, ER and PR were measured by a five-point dextrane-coated charcoal assay in a cytosol fraction of frozen tumor tissue as previously described (9) .
RNA Isolation and cDNA synthesis
The approximately 50-100 mg of tissue frozen in liquid nitrogen was pulverized in cold mortar vessel and extraction of total RNA was performed with acid-phenol guanidine method (10) . Quality of RNA preparation was verified on agarose gels stained with ethidium bromide. RNA was dissolved again and concentration was determined spectrophotometrically. Total RNA (1µg) was reverse transcribed in 20µl reaction volume with Omniscript RT Kit (Qiagen, Hilden, Germany) using the 10µM random hexamer and 1µM oligodT (15) primer according to manufacturer conditions (reverse transcription was performed 60 min
Real-time PCR analysis
All PCR reactions were performed using a 7000 Sequence Detection System (Applied Biosystems). PCR was carried out in 25 µl reaction volume containing the 1x TaqMan Universal PCR Master Mix (Applied Biosystems), 1x TaqMan Pre-Designed Gene Expression Assay specific for target transcript sequence and cDNA diluted with water (1:10). Relative quantity of target transcripts ER 1 or ER -ferences relative to calibrator, or 1x sample, according to equation: N = 2 .
target transcripts (ER 1 and ER -actin gene (endogenous control) (11) .
Statistical analysis
Since levels of expression show non-Gaussian distribution, nonparametric tests (Spearman, Mann-Whitney and Chi square) were used for the analysis of correlation with clinical and histopathological parameters.
RESULTS
Relative quantities of ER 1 and ER -tion to calibrator and normalized to the actin as a reference gene. Distributions of RNA expression levels for both transcripts were the same as distribution of ER and PR proteins and according to Kolmogorov-Smirnov test, values vary significantly from the pattern of a normal distribution.
Expression of ER 1 and ER breast tissue
Concerned with fact that there are no cut-off values for ER expression of mRNA level, and
In this study we classified the BC samples according to expression of ER 1 and ER mRNA as "low expressed" (Tu1), "medium expressed" (Tu2), and "high expressed" (Tu3). Samples with "high expression" (Tu3) of ER 1 were defined as those in which more than three fold differences (in respect to calibrator) were detected; "medium expression" (Tu2) were those between one to three fold differences, and "low expression" (Tu1) were those with less than one fold difference. In the same way, the expression level is defined for the ER difference; Tu2 between two and six fold difference, and Tu1 less than two fold difference. This classification and numbers of samples in each expression group were showed in Table  1 . Expression levels of ER 1 and ER compared with expression level in healthy mammary tissue (N), Table 1 . Samples in "high expression" group (Tu3) does not differ significantly from the expression level in healthy mammary tissue (Tu3 vs. N, Mann-Whitney for 1, p=0.315, Figure 1 ; Tu3 vs. ER Mann-Whitney for and in "low expression" group (Tu1) significantly vary from the expression level in healthy mammary tissue. For ER 1 Tu2 group vs. N, p=0.023, and Tu1 group vs. N, p=0.001 (Mann-Whitney), Figure 1 . For ER (Mann-Whitney). Expression between "low expression" and "medium expression" groups does not differ significantly neither for ER 1, nor for ER It is apparently that Tu3 tumors (those do not differ from expression level in normal tissue) could be considered as "positive" for ER expression, and Tu2 and Tu1 could be considered as "negative" for ER expression. 
Correlation of ER 1 and ER ER and PR
We examined does the expression status of ER 1 and ER ER cytosol proteins) and 24 were ER -negative. According to PR status, 20 samples were Analysis of association between ER and PR protein levels shows no correlation with expression of the wild type of estrogen receptor beta (ER 1). We found correlation between ER -menopausal patients (ER patients significant inverse correlation exist between ER (Spearman, =-0.335, p=0.04). There is no correlation between ER or PR in the group of premenopausal patients (results not shown). In order to examine does the ER expression correlates with established percentage of endocrine unresponsive patients, we analyze expression of both ER transcripts in groups defined by the ER ER -Assignment of the tumors with high expression of ER 1 and ER -tioned groups of patients are parallel to the percentage of endocrine unresponsive ones.
DISCUSSION
Majority of available data about ER expression in clinical samples come from the immunohistochemical studies. Quantification of ER expression on RNA level is justified, since the ER mRNA increases in parallel with the increase in protein level as showed by Cheng et al (12) , indicating that regulation of ER expression is on transcriptional level. In this study, we performed the specific and sensitive TaqMan pre-designed assay for qPCR to quantify mRNA of ER 1 (wt isoform) and ER of ER 2 isoform. ER In examined samples of BC we found that there are two groups, according to expression of ER 1 and ER i) those that are not different compared to normal mammary tissue (referred as ER -positive or "high expressed" (Tu3)), Table 1, Figure 1 and 2. ; ii) and those in which expression levels significantly varies from normal mammary tissue (referred as ERnegative or "medium expressed" (Tu2) and "low expressed" (Tu1)), Table 1, Figure 1 and 2. We found no correlation between expression of ER 1 mRNA, measured by qRT-PCR and ER measured by ligand binding assay. Other authors also report (in immunohistochemical studies) that there is no correlation between ER and ER expression on protein level (13, 14) . The absence of correlation of ER 1 expression with clinical and histopathological parameters (our unpublished results), indicate that its expression level could be an independent predictive marker in BC, but its predictive value remains to be established. Interestingly, little is known about expression of ER fifth exon results in frame shift in reading frame of protein, generating five alternative amino acids, and stop codon after them, which results in truncated protein without ligand binding domain. In cell transfection studies (16) , it was shown that ER possesses dose dependent, inhibitory activity against and ER in 293T cell line. A similar activity, also in eukaryotic cell culture system, has its counterpart, ER the ER on ERE reporter genes. Our finding of inverse correlation of ER in postmenopausal patients are in concordance with in vitro study of Inoue and coworkers (16) and may reflect the inhibitory activity of this truncated protein in vivo against transcriptional activity of ER receptor. Inverse correlation of PR and ER 2 was also reported by Saji and coworkers (17) . Their data, together with our result that ER in vivo suggest that high expression of some ER isoforms may underlie the emergence of ER cells. Inverse association between expression of ER be the consequence of inhibition of estrogen-induced activity of ER by hetero-dimerization with truncated protein encoded by that this inverse correlation comes from postmenopausal subset of patients, points out that this inhibitory activity might be detectable in vivo only when levels of circulating estrogen is low. of concomitantly "highly expressed" ER 1 and ER -centages of endocrine unresponsive patients. Poola and coworkers (15) recently published similar results where they show that two isoforms of ER receptor ( 1 and 5) are highly expressed in ER -negative tumors. Biochemical explanation for this occurrence is that in the absence of ER the ER can be mediator of estrogen signaling as suggested by Poola (15) . Moreover, there are data that tamoxifen may have agonistic effect on ER in HeLa cells and BC cell lines. At the same time, high level of ER with ER (16)) may suppress the ER activity. Although it is widely documented that the decreased expression of ER correlates with tumor emergence and progression, the role of this receptor in tamoxifen resistance remains unclear. Our approach in defining of ER mRNA positive and negative is based on comparison between normal and malignant tissue is justified, since we obtained results comparable with data obtained in immunohistochemical studies. This approach may be helpful in future studies dealing with clinical significance of ER . In conclusion, we point out the necessity for analyzing the complete isoform profiles of ER , ER and PR in clinical samples, since it is possible that one pattern of isoforms expression may be a cause of tamoxifen resistance and the other might be a marker of sensitivity.
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